"MDxHealth SA OTC MDXHF.BR httpstudio.financialcontent.comprnewsPageQuoteTickerMDXHF.BR today announces that a new study validates the costeffectiveness of the SelectMDx for Prostate Cancer test a noninvasive urinebased liquid biopsy test that helps identify patients at increased risk of aggressive prostate cancer. The SelectMDx test can help predict the likelihood that clinically significant prostate cancer will be found by a biopsy. The study published in The Journal of Urology https led by researchers at the Vanderbilt University Medical Center was designed to elucidate the costeffectiveness of SelectMDx in a population of U.S. men with elevated PSA a marker of prostate cancer risk. Researchers analyzed the impact of utilizing the noninvasive diagnostic test prior to prostate biopsy. The primary objective was to characterize changes in health outcomes measured in qualityadjusted life years and a secondary objective was evaluating healthcare costs. The researchers found that incorporating SelectMDx resulted in an average gain of . life years or approximately  days in full health gained at a costsavings of  for each patient undergoing biopsy. Extrapolating these data to a conservative estimate of  patients per year undergoing biopsy resulted in  life years in full health gained with an annual cost saving of more than  million for each cohort. This study demonstrated that routine use of SelectMDx to guide biopsy decisionmaking improves health outcomes and lowers healthcare costs associated with prostate cancer risk assessment in a population of U.S. men said Dr. Matthew Resnick from the departments of Urologic Surgery and Health Policy at Vanderbilt University Medical Center Nashville TN. We believe that this strategy improves the value of conventional risk assessment strategies through improvements in both quality and cost the numerator and denominator of the health care value equation. Every year . million men in the U.S. undergo a prostate biopsy.i Although a biopsy is the only way to diagnose prostate cancer the procedure is invasive and results in complications in  percent of patients with  percent hospitalized for infection within  days.iiiiiiv Common complications from a prostate biopsy may include bleeding infection sepsisbacteremia urinary symptomsretention and sexual dysfunction. While biopsy is the only path to prostate cancer diagnosis no man wants to nor should have to go through the uncomfortable costly procedure if it can be avoided said Dr. Jan Groen Chief Executive Officer of MDxHealth. We developed SelectMDx to help reduce unnecessary biopsies and now we have the data to show how we can both improve outcomes and save the system money. The full paper is accessible via the online edition of The Journal of Urology. About SelectMDx for Prostate Cancer  SelectMDx for Prostate Cancer is a proprietary urinebased molecular diagnostic test that offers a noninvasive liquid biopsy method to assess a mans risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive potentially lethal prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to  thereby improving quality of life and lowering healthcare costs per patient. SelectMDx is available in the US and all EU member states. Since the introduction of the SelectMDx test in mid over  patients have been tested and  commercial contracts have been signed with US based insurance companies. The test has been included in the  European Association of Urology EAU clinical guidelines. About MDxHealth  MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The companys tests are based on proprietary genetic epigenetic methylation and other molecular technologies and assist physicians with the diagnosis of urologic cancers prognosis of recurrence risk and prediction of response to a specific therapy. The Companys European headquarters are in Herstal Belgium with laboratory operations in Nijmegen The Netherlands and US headquarters and laboratory operations based in Irvine California. For more information visit mdxhealth.com http and follow us on social media at twitter.commdxhealth httpstwitter.commdxhealth facebook.commdxhealth httpstwitter.commdxhealth and linkedin.comcompanymdxhealth httpslinkedin.comcompanymdxhealth. For more information MDxHealth  Kenneth Kami     kenneth.kamimdxhealth.com mailtokenneth.kamimdxhealth.com  CURA Strategies  ThyAnn Nguyen     thyann.nguyencurastrategies.com mailtothyann.nguyencurastrategies.com This press release contains forwardlooking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks uncertainties and other factors which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict may depend upon factors that are beyond the companys control and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forwardlooking statements in this release to reflect any change in its expectations with regard thereto or any change in events conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of  as amended or in compliance with an exemption therefrom and in accordance with any applicable U.S. securities laws. NOTE The MDxHealth logo MDxHealth ConfirmMDx SelectMDx AssureMDx PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.   i NCI Seer Data .   http  ii Gershman et al. Eur Uro   iii Loeb et al. Eur Uro .  iv Loeb et al. J Urol. . SOURCE MDxHealth Related Links http"